Pricing Log in Create free account
Friday 6 November 2026 Export GSK’s income statement to Excel — free account

GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.

Revenue
+3.75%
EPS
−14.7%
Free cash flow
+62.4%
Total debt
+33.2%

Quarter to September 2026, against a year earlier

50.43 0.02 +0.04%
Market cap
$101.0B
P/E
16.7×
Fwd P/E
14.6×
Dividend yield
3.60%
F-score
9/9
Altman Z
2.12
Beneish M
−2.46
Dividend safety
54/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.22%

Capital & Financial Ratios $m

Size
Market Cap 101,040.00
Revenue ttm 44,942.90
Net income ttm 6,303.65
Free cash flow ttm 8,830.02
Net debt Q 27,753.36
Valuation
P/E 16.73
Forward P/E 14.60
Price / sales 2.25
Forward P/S Powerpack
Price / FCF 11.44
Price / book 4.09
Financial health
Current ratio Q 0.86 (below 1: weak)
Debt / equity Q 1.29
Interest coverage Q 9.71
Growth
Revenue growth Q +3.75% (above 0%: growing)
Operating income growth Q −18.15% (below 0%: shrinking)
EPS, this year +1.73%
EPS, next year A +4.02%
Revenue, next year A +4.85%
EPS, past 5 yrs +0.04%
EPS, next 5 yrs A +3.57%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 2.8×; over the ten years it ranged from 1.7× in 2022 to 3.9× in 2019.
P/E against its own 10 years 47.56%
10-year low 10-year high
P/S against its own 10 years 46.53%
10-year low 10-year high
P/B against its own 10 years 26.15%
10-year low 10-year high
EV/Sales against its own 10 years 59.99%
10-year low 10-year high
EV/FCF against its own 10 years 24.67%
10-year low 10-year high

Dividends raised 2 years running

Yield
3.60%
Annual rate
1.82
Payout ratio
60.9%
Growth, 2017–25
−5.12%/yr
  1. 2.60 ’17
  2. 2.67 ’18 +3
  3. 2.55 ’19 −4
  4. 2.56 ’20 +0
  5. 2.75 ’21 +7
  6. 1.89 ’22 −31
  7. 1.40 ’23 −26
  8. 1.56 ’24 +11
  9. 1.71 ’25 +9
  10. 0.93 ’26e −46
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 6,608 5,112 4,651 4,122
Receivables 9,650 9,361 10,232 11,465
Inventory 6,839 7,244 7,812 8,473
Other — — — —
23,191 21,720 23,090 24,067
2023 2024 2025 Q'26
Payables 19,708 19,597 20,283 21,025
ST’ Debt 3,499 3,002 3,972 2,691
Other 2,377 4,230 3,297 3,239
26,206 27,727 28,208 27,866

Compound Annual Growth %

10y 5y 3y
Sales 1.65% (0.32%) 5.90%
Cash Flow 10.02% (1.19%) 3.69%
Earnings (5.21%) 0.42% (25.86%)
Book Value 4.48% (4.66%) 19.00%

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 1.40 Actual 1.47

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2025 0.64 0.68 Beat by 0.04
Mar 2026 1.16 1.24 Beat by 0.08
Jun 2026 1.27 1.36 Beat by 0.09
Sep 2026 1.40 1.47 Beat by 0.07
Dec 2026 0.76 — Reports 3 February 2027

EPS $

Mar Jun Sep Dec Year
’26 1.15 0.29 1.12 — —
’25 1.00 0.94 1.34 0.42 3.72
’24 0.65 0.72 (0.04) 0.26 1.59
’23 0.90 1.00 0.90 0.21 2.98
’22 1.20 0.52 5.94 0.92 9.19
’21 0.74 0.96 0.80 0.50 3.01
’20 1.00 1.41 0.81 0.45 3.71
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 10,280 11,286 11,952 — —
’25 9,466 10,666 11,521 11,425 43,078
’24 9,337 9,950 10,420 10,388 40,095
’23 8,444 8,988 10,313 9,980 37,725
’22 13,123 8,699 9,221 5,228 36,271
’21 10,229 11,311 12,516 12,853 46,910
’20 11,644 9,461 11,169 11,509 43,783
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1,537 3,604 3,789 — —
’25 1,442 2,887 3,035 2,844 10,208
’24 1,215 1,399 2,881 2,880 8,375
’23 64 1,638 2,819 3,897 8,419
’22 3,411 1,833 1,231 2,681 9,157
’21 456 1,812 3,502 5,164 10,935
’20 1,236 3,386 1,302 4,914 10,838
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1,060 3,127 3,075 — —
’25 975 2,020 1,893 1,568 6,455
’24 536 848 1,877 1,553 4,815
’23 (565) 963 2,189 2,965 5,553
’22 2,625 1,354 886 1,923 6,787
’21 472 1,058 1,918 4,715 8,163
’20 948 3,553 491 4,671 9,662
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 37,798 38,904 41,140 43,100 43,783 46,910 36,271 37,725 40,095 43,078 44,943 +1.5% 45,168 47,241 48,787 +4.2%
Gross margin, % 66.69 65.74 66.77 64.85 65.68 65.99 67.42 71.76 71.16 72.40 72.64 +5.7 pt
EBT 2,628 4,543 6,407 7,944 8,947 7,483 6,961 7,543 4,443 9,760 7,240 +15.7%
EBT margin, % 6.95 11.68 15.57 18.43 20.43 15.95 19.19 19.99 11.08 22.66 16.11 +15.7 pt
Net income 1,439 2,795 5,401 6,727 8,202 7,008 6,087 6,603 3,771 8,293 6,304 +21.5%
Per share, $
Per share, $ Revenue 19.44 19.91 20.93 21.78 22.00 23.44 18.02 18.62 19.67 21.27 22.42 +1.0%
Earnings 0.64 1.01 2.46 3.00 3.71 3.01 9.19 3.02 1.61 3.72 3.01 +21.7%
Cash flow 4.53 4.56 5.72 5.18 5.45 5.46 4.55 4.16 4.11 5.04 5.87 +1.2%
Capex (1.37) (1.24) (0.93) (1.07) (0.59) (1.39) (1.18) (1.41) (1.75) (1.85) (1.47) +3.4%
Free cash flow 3.16 3.33 4.79 4.10 4.85 4.08 3.37 2.74 2.36 3.19 4.41 +0.1%
Book value 3.46 2.30 2.49 11.85 13.42 14.66 6.20 7.86 8.20 10.39 12.32 +13.0%
Shares, m 1,944 1,954 1,966 1,979 1,990 2,001 2,013 2,026 2,039 2,026 2,012 +0.5%
Valuation, ×
Valuation, × P/E 80.92 46.74 19.59 19.74 12.47 18.30 4.07 12.42 21.14 13.22 16.73 24.9
P/S 2.51 2.32 2.28 2.70 2.09 2.35 1.96 2.01 1.72 2.31 2.25 2.2
P/B 14.05 20.06 19.15 4.96 3.43 3.76 5.69 4.77 4.12 4.72 4.09 8.5
EV/Sales 3.00 2.75 2.99 3.45 2.70 2.93 2.40 2.43 2.13 2.74 2.87 2.8
EV/FCF 18.42 16.47 13.09 18.30 12.22 16.83 12.82 16.53 17.76 18.29 14.58 16.1
Cash, $m
Cash, $m Operating cash flow 8,805 8,916 11,240 10,241 10,838 10,935 9,157 8,419 8,375 10,208 11,775 +1.7%
Capex (2,671) (2,414) (1,831) (2,125) (1,176) (2,772) (2,370) (2,866) (3,560) (3,753) (2,945) +3.9%
Free cash flow 6,134 6,502 9,409 8,116 9,662 8,163 6,787 5,553 4,815 6,455 8,830 +0.6%
Balance, $m
Balance, $m Working capital (3,104) (13,741) (7,427) (5,821) (2,441) (6,870) (2,525) (3,015) (6,006) (5,118) (3,799) +5.7%
Net debt 18,497 16,896 29,256 32,307 26,486 27,021 15,981 15,805 16,595 18,716 27,753 +0.1%
Shareholders’ equity 6,726 4,497 4,901 23,440 26,717 29,347 12,488 15,916 16,723 21,041 24,695 +13.5%
Returns, %
Returns, % ROA 1.53 2.59 6.44 6.62 7.20 5.69 20.20 8.30 4.41 9.63 6.53 +8.1 pt
ROIC 8.72 15.39 13.39 9.97 11.74 9.45 17.47 16.53 9.64 16.44 9.61 +7.7 pt
ROE 12.18 35.19 102.91 41.86 29.43 21.51 88.44 43.16 20.16 39.92 25.48 +27.7 pt
People
People Employees 99,827 99,349 95,490 99,437 94,066 90,096 69,400 70,200 68,629 66,841 — (4.4%)
Revenue/emp, $m 0.38 0.39 0.43 0.43 0.47 0.52 0.52 0.54 0.58 0.64 — +6.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

GSK PLC Sponsored ADR vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AZN AstraZeneca PLC $289.8B 26.3× 24.5× +6.70% (above 0%: growing) +22.50% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $248.8B 26.6× 29.6× +8.45% (above 0%: growing) +19.44% (above 0%: growing) −0.16% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.33% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $170.3B 42.2× 18.9× −0.43% (below 0%: shrinking) −7.98% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $134.8B 9.9× — +4.47% (above 0%: growing) −18.68% (below 0%: shrinking) +71.57% (above 0%: growing) 78.21% 34.48% Compare
BMY Bristol Myers Squibb Company $129.0B 14.0× 11.9× +6.93% (above 0%: growing) −2.02% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40% Compare
SNY Sanofi $111.8B 23.2× — +13.89% (above 0%: growing) +8.21% (above 0%: growing) +99.60% (above 0%: growing) 76.16% 28.53% Compare
GSK GSK PLC Sponsored ADR $101.0B 16.7× 14.6× +3.75% (above 0%: growing) −14.73% (below 0%: shrinking) +62.44% (above 0%: growing) 73.11% 23.93%
BIIB Biogen Inc. $36.1B 104× 47.4× +10.63% (above 0%: growing) n/m −69.25% (below 0%: shrinking) 73.31% 4.58% Compare
Median of peers $152.6B 26.3× 24.5× +6.88% −2.02% +11.01% 75.94% 27.80%

All 21 Drug Manufacturers General stocks →

GSK PLC Sponsored ADR (GSK) Latest News

1 Nov

Impact 3 · · Simply Wall St.

29 Oct

Impact 3 · · Simply Wall St.

28 Oct

Impact 4 · · MarketBeat
Impact 4 · · Investing.com earnings
Impact 4 · · Proactive Investors
Impact 3 · · Associated Press
Impact 3 · · Zacks
Impact 3 · · Zacks
Impact 3 · · Proactive Investors
Impact 3 · · Investing.com

27 Oct

Impact 4 · · MarketBeat
Impact 4 · · Simply Wall St.
Impact 3 · · Zacks

24 Oct

Impact 4 · · 24/7 Wall St.

23 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

22 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.
Impact 3 · · Zacks

21 Oct

Impact 4 · · Zacks
Impact 4 · · Business Wire
Impact 4 · · Proactive Investors
Impact 4 · · Zacks
Impact 3 · · Zacks

20 Oct

Impact 4 · · GlobeNewswire
Impact 4 · · Business Wire
Impact 4 · · Zacks

19 Oct

Impact 4 · · Business Wire
Impact 4 · · Proactive Investors
Impact 3 · · Simply Wall St.

GSK metrics, ten years each

stockrow.com/GSK · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com